InspireMD, Inc. (NSPR) Earnings Call Transcripts
InspireMD, Inc.'s Latest Earnings Call - May 13, 2026
InspireMD, Inc. (NSPR:US) reported significant developments during its earnings call for Q1 FY2026, focusing on its flagship product, the CGuard stent. The company highlighted a shift in the carotid artery disease treatment landscape, with endovascular procedures gaining ground over traditional surgery. Revenue figures and earnings were not explicitly disclosed in the transcript, but management emphasized the strategic importance of recent clinical trial successes and regulatory approvals. Forward guidance was not provided, but management expressed confidence in capturing a larger market share as the industry trend moves towards stenting.
Reported metrics
| Metric | Value |
|---|---|
| Market Share Shift | 45% endovascular in 2025 (positive) |
| Clinical Trial Success | Best-in-class outcomes (beat) |
| Financing | $114 million financing (neutral) |
| PIPE Investment | $40 million (neutral) |
Guidance from management
Management did not provide specific forward guidance but indicated confidence in capturing a larger market share as the industry shifts towards stenting.
What analysts pressed on
Analysts are likely concerned about the pace of market adoption and the company's ability to maintain its competitive edge as larger players may enter the market. The lack of specific revenue and earnings guidance could also be a point of concern.
Main topics on the call
- Shift to Endovascular Procedures — Management noted a significant shift from surgical to endovascular procedures in carotid artery disease treatment, stating, 'In 2025, it was about 45% endo... within the next several years, this will be looking like the ...
- CGuard Stent Clinical Success — The CGuard stent demonstrated 'best-in-class outcomes' in clinical trials, with management highlighting its superior safety and efficacy compared to competitors.
- Regulatory and Market Expansion — The company is leveraging recent regulatory approvals and clinical trial data to expand its market presence, particularly in the U.S., where 'stenting was shown to be statistically superior' in certain trials.
- Financial Position and Funding — InspireMD discussed its strong financial backing with recent financing rounds, including a $40 million PIPE, to support commercialization efforts.
Read the full InspireMD, Inc. transcript (May 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About InspireMD, Inc.
InspireMD, Inc. (NSPR) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 29 calls on record spanning March 10, 2020 to May 13, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 29 InspireMD, Inc. earnings call transcripts on record, spanning March 10, 2020 to May 13, 2026. Based on this history, InspireMD, Inc. reports quarterly. The most recent call on file is dated May 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NSPR
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Calls on record
- 29
- First call
- March 10, 2020
- Most recent
- May 13, 2026
- Reporting cadence
- quarterly